Thursday, 28 June 2012

BioSystems - Product Pipeline Analysis

Biosystems International (BSI) is a biotechnology and pharmaceutical company, based in France. The company creates cutting edge blood-based diagnostics for early cancer detection and innovative antibody microarrays for blood-based biomarker research. It operates through product segments such as PlasmaScan and Quantiplasma Antibody Libraries. PlasmaScan 80 / PlasmaScan380 antibody arrays contain 80 and 380 (respectively) different mABs each reacting with different epitopes of the human plasma proteome. QuantiPlasma antibody library, allow precise proteome profiling without sample labeling. BSI provides service such as sample preparation and mAB production and characterization. The company is partnered with Amundi Asset Management, Gedeon Richter, Northeastern University, Randox Laboratories, Ltd and NKTH among others. BSI is headquartered in Evry Cedex, France.

This report is a source for data, analysis and actionable intelligence on the BioSystems International portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.